The microbiome sample preparation technology market size is estimated to be USD 295.8 million in 2022 and is expected to witness a CAGR of 6.54% during the forecast period 2023-2033. Rising investment for microbiome research, development of microbiome-based therapies, along with lowering sequencing costs, and continuous decline in the price of genomic testing are factors contributing to the market growth. Additionally, increasing use of instruments and consumables in the North America is expected to propel the market growth. However, lack of thorough research, regulatory regulations are expected to hinder the growth.

Rising investment for microbiome research is predicted to fuel the market growth. The demand for microbiome sample preparation technology from academic and research institutions is projected to increase as grants and funding programmes for microbiome-based research are expanded. Five academic institutions, including Harvard School of Public Health, Columbia University Health Sciences, Graduate School of Public Health and Health Policy, and New York University School of Medicine, were awarded grants from the National Cancer Institute in 2022. The grant was worth between USD 387,513 and USD 717,936.

Development of microbiome-based therapies is projected to support the market growth. The demand for microbiome sampling technologies is directly impacted by treatments based on the microbiome. In recent years, it has been found that the chemicals made by the gut microbial community that influence cellular and organismal processes have a major impact on host physiology since they act as an efficient channel of communication in host-microbe interactions. For instance, Digbi Health, a startup that provides care for people with genetic and gut microbiome issues, took part in Novo Nordisk’s Global Prevention Accelerator Program in August 2022. Selected participants are expected to receive investment support from Novo Nordisk as a result of the initiative, which was created to invite potential start-ups to submit their solutions.

Segmentation

By Product

The market is categorized into consumables and instruments. In the global market, the consumables segment accounted for the largest revenue share in 2022 owing to the rising demand for DNA library preparation kits and purification/extraction kits. For instance, in June 2021, MolGen, a innovative producer of DNA/RNA extraction technology, and SpeeDx Pty, Ltd., an Australia-based firm specialising in molecular diagnostics solutions, teamed for the supply and marketing of their goods across Europe and the Asia Pacific. By integrating the diagnostic assay technology of SpeeDx and MolGen’s DNA/RNA extraction portfolio, the agreement is expected to be advantageous for both businesses.

By Workflow

The market is categorized into quality control, sample extraction, library quantification, fragmentation, pooling, target enrichment, library preparation, and sample quantification. In 2022, the sample extraction segment accounted for the highest revenue share due to surging usage of extraction method and increasing prevalence of chronic disorders. To comprehend the impact of the microbiome on human health, microbiome research is one of the crucial areas of focus for continuing studies in medicine and diagnostics. Studies in this field rely on reliable extraction techniques that can extract DNA effectively and remove sample inhibitors. Depending on the sample’s makeup, a different extraction technique may be performed since some cell types may require more aggressive extraction techniques.

By Disease Type

The market is categorized into gastrointestinal disorders, autoimmune disorders, and cancer, others. In the global market, the gastrointestinal disorders segment accounted for the largest revenue share in 2022 owing to increasing gastrointestinal problems. Microbiome sample analysis can be used to diagnose most GI diseases, including IBS, C. difficile, and Crohn’s disease. IBD, which comprises ulcerative colitis (UC) and Crohn’s disease (CD), is a relapsing-remitting inflammatory gastrointestinal disease that damages the intestines to varied degrees and can result in local and extra-intestinal issues.

By Application

The market is categorized into RNA sequencing, DNA sequencing, single cell sequencing, methylation sequencing, whole-genome sequencing, metagenomics, and others. In 2022, the DNA sequencing accounted for the highest revenue share due to the fact that sequencing is important in many domains, from fundamental biology to the evolution of humans. Additionally, technological developments that ensure affordable sequencing are anticipated to enhance industry expansion. For instance, in June 2022, a start-up company called Ultima Genomics said during a meeting in Florida that it could deliver human genomes for USD 100, or one-fifth of the prevailing fee, given the advancement of existing technology. However, Illumina currently holds the majority of the market.

By End User

The market is segmented into diagnostic labs, pharmaceutical & biotechnology, and others. In 2022, the diagnostic labs segment accounted for the largest revenue share owing to the fact that diagnostic laboratories are one of the major industries where microbiome sampling is used. As a result, it is used to identify autoimmune disorders, different tumors, gastrointestinal problems, and numerous other diseases. Another important growth factor is the expanding number of clinical trials using microbial analysis to identify various medical disorders.

Regional Markets

North America held the largest revenue share in the microbiome sample preparation technology market in 2022, and it is predicted to continue to do so throughout the forecast period. This is attributed to increasing funding options, alliances and cooperative efforts by regional participants, and the growing usage of technical advancements in the United States. For instance, Persephone Biosciences, a company that conducts microbiome research, and Janssen Biotech reached a deal in September 2021 to use patient samples from Janssen’s cancer clinical study. Additionally, the high penetration of ongoing genomic research initiatives across the region has been linked to the increased usage of instruments and consumables in the North American market. The Asia Pacific is predicted to experience the quickest growth throughout the projected period due to the strong commercial expansion of new start-ups and the strategic choices made by multinational corporations. For instance, in South Korea, CJ CheilJedang funded 4 billion won ($3.56 million) in KO Biolabs in 2019, which is creating psoriasis and asthma medicines based on the microbiome. The business also purchased a 44% share in ChunLab, a developer of technology for precise microbiome investigation, in July 2021 for 98.3 billion won.

Competitor Insights

Some of the key players operating in the microbiome sample preparation technology market are QIAGEN, BGI, Bio-Rad Laboratories, Inc., Perkin Elmer, Inc., Agilent Technologies Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., and Danaher Corporation.

To enhance their market position, major firms are developing and putting into practise a variety of strategies such as new product launches, investments in startups or complementary businesses through mergers and acquisitions, regional growth, and strategic partnerships.

• For instance, Bio-Rad Laboratories introduced the SEQuoia RiboDepletion Kit in May 2021 to simplify the process of preparing RNA-Seq libraries. With this kit’s ability to preserve sRNA transcripts, researchers can target uncommon transcripts or deal with small/degraded sample sizes. The company’s position in the market was reinforced as a result.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, workflow, disease type, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Microbiome Sample Preparation Technology Market Report 2022 – 2033

Product (Revenue, USD Million)

• Consumables
• Instruments

Workflow (Revenue, USD Million)

• Quality Control
• Sample Extraction
• Library Quantification
• Fragmentation
• Pooling
• Target Enrichment
• Library Preparation
• Sample Quantification

Disease Type (Revenue, USD Million)

• Gastrointestinal Disorders
• Autoimmune Disorders
• Cancer
• Others

Application (Revenue, USD Million)

• RNA Sequencing
• DNA Sequencing
• Single Cell Sequencing
• Methylation Sequencing
• Whole-Genome Sequencing
• Metagenomics
• Others

End user (Revenue, USD Million)

• Diagnostic Labs
• Pharmaceutical & Biotechnology
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA